ASCENTAGE

6855
26.1207.05% ( -1.980 )
Delay Closed: Nov 16, 16:08:11

Overview

ASCENTAGE (6855)

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related d...

Open
28.300
High
28.300
Low
25.540
Prev. Close
28.100
Volume
5.32M
Turnover
138.95M
Avg Price
26.106
Bid/Ask Ratio
45.83%
Amplitude
9.82%
52wk High
69.100
Volume Ratio
1.60
Turnover Ratio
1.42%
52wk Low
25.540
HK Mkt Cap
9.79B
Market CapHKD
9.79B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-4.51
EPSDynamic
-5.02
EPSStatic
--
BVPS
1.71
P/B
15.29
HK Shares
374.96M
Dividend YieldTTM
--
DividendTTM
--
Shares
374.96M
Min lot size
100
Currency
HKD

ASCENTAGE Analyst Rating

View more

Forecast & Rating

Aug 27, 2026
Price forecast
HK$71.75174.69%
Forecast & RatingStrong buy
6analysts
  • Strong buy83.33%
  • Buy16.67%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    Ascentage Pharma fell roughly 7.0% in a spike-and-fade session, opening at HK$28.30, sliding to HK$25.56 by 10:45 to print a fresh 52-week low, rebounding to HK$26.48 in the afternoon before closing near HK$26.12 on about 5.32 million shares. The drop came even though Lisaftoclax was added to China's 2026 national reimbursement drug list and coverage for olverembatinib was renewed; the headlines failed to draw buyers and the session extended losses instead. Q2 2026 revenue rose 36.31% year on year to HK$174.5 million, yet the net loss widened 45.72% to HK$471.7 million, leaving PB at 15.29x and PE negative. The stock is down 48.68% year to date, 62.2% below its HK$69.1 52-week high, and trades beneath MA20 at HK$28.82 and MA60 at HK$30.48. Still, an oral ASH presentation for APG-5918 offers some offset.

  2. Nov, 9

    Ascentage Pharma gapped up 2.8% and spiked to HK$30.78 in the morning session before fading, closing at HK$29.86 for a 1.98% gain on 1.78 million shares worth HK$53.86 million and a thin 0.48% turnover; the session low of HK$29.68 printed at 15:54 BJ, a classic spike-and-fade profile. The move extends momentum from the ASH 2026 Annual Meeting selection of multiple company studies, including an oral presentation of first clinical data for APG-5918, on top of a 9.01% gain last week and mostly buy ratings from brokers. Fundamentals remain in the investment phase: Q2 2026 revenue rose 36.31% year on year to HK$174.5 million, yet the net loss widened 45.72% to HK$471.7 million and net margin stood at -270%. The shares sit above the MA20 of HK$28.99 but below the MA60 of HK$31.01, down 41.34% year to date, 56.94% below the 52-week high of HK$69.35 and only 15.74% above the 52-week low of HK$25.80. Though a broad pullback across Hong Kong biotech names in recent sessions may keep capping upside.

  3. Nov, 5

    Ascentage Pharma rose about 6.7% in a low-open, high-close session, driven mainly by news that first clinical data for APG-5918 was selected for an oral presentation at the 2026 ASH Annual Meeting. The stock started at HK$29.28 in the morning session, touched an intraday high of HK$30.70, then traded in a narrow HK$29.98-30.48 range in the afternoon before closing at HK$30.24 on 3.62 million shares and roughly HK$109 million turnover. The move extended a run of catalysts, with multiple company studies selected for ASH 2026 and Lisaftoclax earlier winning Breakthrough Therapy Designation in mainland China. Still, the shares remain in repair mode: they are down about 40.6% year to date, 56.4% below the 52-week high of HK$69.35, just above the MA20 of HK$28.85 but below the MA60 of HK$31.25, while the 52-week low of HK$25.80 was set on November 2.

  4. Nov, 4

    Ascentage Pharma rose 7.2% to HK$28.34 and closed at the session high after a low-open, afternoon-led rally from an intraday trough of HK$26.40; turnover reached HK$82.7 million, with 2.13 million shares changing hands in the afternoon, roughly 70% of the day's 3.0 million. The move followed China's Breakthrough Therapy Designation for Lisaftoclax (APG-2575) in first-line CLL/SLL, alongside Chinese innovative-drug data released at the ESMO annual meeting and a trustee purchase of 200,000 shares under the 2022 RSU scheme. Fundamentals still mix expansion with widening losses: Q2 revenue of HK$174.5 million grew 36.3% year on year, while the net loss of HK$471.7 million widened 45.7% and EPS was -HK$1.26. Even after today's gain the stock sits below its MA20 of HK$28.78 and MA60 of HK$31.36, is down 44.3% year to date, 59.5% below the 52-week high of HK$69.95 (26 October 2025) and only 9.8% above the HK$25.80 low set on 2 November; though a net margin of -270% shows the loss burden is unresolved.

  5. Oct, 28

    Ascentage Pharma reversed an early dip and touched the session high of HK$29.300 in the afternoon, closing at that level for a 5.02% gain from HK$27.900, as core asset Lisaftoclax (APG-2575) received Breakthrough Therapy Designation in mainland China for first-line CLL/SLL, reinforced by ESMO annual meeting data on Chinese innovative drugs; the morning low of HK$28.300 was absorbed quickly on 1.09 million shares and HK$31.31 million turnover, while a trustee bought another 200,000 shares under the 2022 restricted share unit plan. Fundamentals remain uneven: Q2 2026 revenue rose 36.31% year on year to HK$174.5 million even as the net loss widened 45.72% to HK$471.7 million, with EPS of -HK$1.2648. The price still sits below MA20 of HK$29.405 and MA60 of HK$31.948, down 42.44% year to date, 58.17% below the 52-week high of HK$70.05 and only 8.04% above the 52-week low of HK$27.12. How fast the new indication converts commercially remains the variable to watch.

News

Bullish vs. Bearish — Last 3 Months

4.1k followers · 0 opinions
▲Bullish50%
50%Bearish▼